Chris Hollowood
Chris is the Chief Executive Officer of Syncona Investment Management Ltd.
He has been instrumental in the foundation and development of Syncona's gene therapy strategy, where it has founded companies focused on the eye, the liver, the kidney, and central nervous system. He is Chairman of Beacon, Freeline, SwanBio, Purespring, Mosaic and Forcefield and was also previously Chairman of retinal gene therapies Nightstar, which was sold to Biogen in 2019 for $877 million, and Gyroscope, which was sold to Novartis for up to $1.5 billion in 2022.
Previously, Chris was a partner of Apposite Capital LLP, a venture and growth capital healthcare investment company. Before Apposite, Chris had roles with Bioscience Managers Ltd, Neptune Investment Management Ltd and in the pharmaceutical industry. Chris holds a degree in Natural Sciences and a PhD in Organic Chemistry, both from the University of Cambridge.
Syncona portfolio companies
- Freeline Therapeutics (Chair)
- SwanBio Therapeutics (Chair)
- Purespring Therapeutics (Chair)
- Mosaic Therapeutics (Chair)
- Beacon Therapeutics (Chair)
